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Abstract
V-type immunoglobulin domain-containing suppressor of T-cell activation (VISTA) is a negative
checkpoint regulator (NCR) involved in inhibition of T cell-mediated immunity. Expression
changes of other NCRs (PD-1, PD-L1/L2, CTLA-4) during inflammation of the central nervous
system (CNS) were previously demonstrated, but VISTA expression in the CNS has not yet been
explored. Here, we report that in the human and mouse CNS, VISTA is most abundantly
expressed by microglia, and to lower levels by endothelial cells. Upon TLR stimulation, VISTA
expression was reduced in primary neonatal mouse and adult rhesus macaque microglia in vitro.
In mice, microglial VISTA expression was reduced after lipopolysaccharide (LPS) injection, during
experimental autoimmune encephalomyelitis (EAE), and in the accelerated aging Ercc1Δ/− mouse
model. After LPS injection, decreased VISTA expression in mouse microglia was accompanied by
decreased acetylation of lysine residue 27 in histone 3 in both its promoter and enhancer region.
ATAC-sequencing indicated a potential regulation of VISTA expression by Pu.1 and Mafb, two
transcription factors crucial for microglia function. Finally, our data suggested that VISTA
expression was decreased in microglia in multiple sclerosis lesion tissue, whereas it was
increased in Alzheimer's disease patients. This study is the first to demonstrate that in the CNS,
VISTA is expressed by microglia, and that VISTA is differentially expressed in CNS pathologies.
KEYWORDS
autoimmunity, cancer, DD1alpha, immune checkpoints, immunotherapy, neurodegeneration,
PD-1H
1 | INTRODUCTION
Immune checkpoint regulators are a group of molecules expressed on
T cells or antigen-presenting cells (APCs), which can provide co-
stimulatory and co-inhibitory signals during T cell activation. This bal-
ance between positive and negative signals is essential for mounting
antigen specific immune responses, while limiting the risk for autoim-
munity. Inhibition of negative checkpoint regulator (NCR) activity has
recently entered the clinic as a treatment for cancer, whereas activa-
tion of NCRs has potential for the treatment of autoimmunity. Thera-
peutic inhibition of NCR activity (immunotherapy) in cancer has been
associated with the development of central nervous system (CNS)
diseases such as encephalitis, myelitis, and exacerbation of multiple
sclerosis (MS) (Cuzzubbo et al., 2017; Yshii, Hohlfeld, & Liblau, 2017).
Accordingly, several studies have reported that inhibition of NCRs
(CTLA4, PD-1, and PD-L1) in mouse experimental autoimmune
encephalomyelitis (EAE), a model of MS, leads to exacerbation of
symptoms (Joller, Peters, Anderson, & Kuchroo, 2012). Furthermore,
blockade of PD-1 in a mouse model of Alzheimer's disease
(AD) improves cognitive performance (Baruch et al., 2016), suggesting
a broad role of NCRs in CNS pathologies. However, the effectiveness
of PD-1 blockade in AD is still not resolved (Latta-Mahieu
et al., 2018).
V-domain Ig-containing suppressor of T cell activation (VISTA) is a
recently discovered NCR, which shares 24% sequence similarity with
PD-L1 (Wang et al., 2011). VISTA (aliases: PD-1H (Flies, Wang, Xu, &
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Chen, 2011); DD1α (Yoon et al., 2015); Dies1 (Aloia, Parisi, Fusco,
Pastore, & Russo, 2010); Gi24 (Sakr et al., 2010)) is expressed on mye-
loid and T cells, and can act as both receptor and ligand (Lines, Sem-
pere, Broughton, Wang, & Noelle, 2014). VISTA expressed on APC
can function as a ligand, suppressing T-cell activation upon binding to
a yet unidentified counter receptor (Wang et al., 2011). In addition,
ligation of VISTA expressed on T cells also leads to inhibition of T cell
activation (Flies et al., 2014). Receptor functions on myeloid cells
include regulation of the cytokine response (Bharaj et al., 2014) and
uptake of apoptotic cells (Yoon et al., 2015). Deficiency of VISTA in
mice increases susceptibility to developing autoimmunity such as EAE
(Wang et al., 2014) and lupus nephritis (Ceeraz et al., 2016).
In the CNS, expression of several NCRs by microglia has been
reported, which is induced under inflammatory conditions (Yshii et al.,
2017). Microglia are the principal innate immune cell type of the CNS,
which acquire diverse functional phenotypes in response to environ-
mental cues (Salter & Beggs, 2014). During CNS pathologies, microglia
lose their homeostatic signature and can shift to an immune-activated
state, as evident from transcriptomic studies (Perry & Holmes, 2014;
Zrzavy et al., 2017). During immune activation, microglia upregulate
inflammatory genes such as genes involved in cytokine production
and antigen presentation. It is now appreciated that in conditions such
as AD and aging, microglia can acquire a phagocytic phenotype
(Galatro et al., 2017a; Krasemann et al., 2017; Varol et al., 2017),
thereby facilitating clearance of debris and toxins. In accordance with
a more protective phenotype during disease, microglia obtain immu-
noregulatory characteristics during inflammation. Induction of NCRs
(e.g., PD-L1) in immune-activated microglia causes inhibition of T cell
activation, and suppression of cytokine production (Duncan & Miller,
2011; Magnus, 2005; Schachtele, Hu, Sheng, Mutnal, & Lokensgard,
2014). Hence, microglial activation is highly heterogeneous and plas-
tic, and can therefore be detrimental or beneficial during disease.
Although the expression and regulation of several NCRs in the
CNS and by microglia has been studied, expression patterns of VISTA
are unknown as noted recently by Yshii et al. (2017). Studies suggest
involvement of VISTA in important functions of monocytes and mac-
rophages, such as cytokine responses and phagocytosis, which exhibit
functional similarities to microglia. As microglia express many NCRs
and are able to acquire immunoregulatory functions during inflamma-
tion, analysis of VISTA expression in these cells could help to under-
stand their role in CNS disease. Furthermore, NCR modulation as a
treatment for cancer and autoimmunity impacts CNS biology, which is
demonstrated by adverse neurological effects during immunotherapy
including encephalitis, myelitis, hypophysitis, and transition from
radiologically isolated syndrome to MS (Cuzzubbo et al., 2017; Yshii
et al., 2017). Hence, investigating expression and expression changes
of VISTA in the CNS might facilitate understanding the impact of NCR
modulation on the CNS.
Here, we assessed VISTA expression in mouse and rhesus
macaque microglia after immune-activation in vitro and in vivo, and
verified our findings using human postmortem tissue. Our results
indicate that VISTA is differentially expressed in microglia during
inflammation and neurodegeneration. Furthermore, we determined
epigenetic changes in the VISTA gene during microglial activation in
mice. These findings provide first evidence of a function of VISTA in
microglia and during CNS pathology.
2 | MATERIALS AND METHODS
2.1 | Animals
All animal experiments were approved by the Netherlands Central
Committee for Animal Experiments and the University of Groningen.
Mice were housed SPF in groups in macrolon cages with ad libitum
access to water and food, and a 12 hr light–dark cycle. Eight-week-
old male C57BL/6 mice (bred in-house) were injected with 1 mg/kg
LPS (E. coli 0111:B4, Sigma-Aldrich, L4391) intraperitoneally and sacri-
ficed 24 hr later. To generate Ercc1Δ/− mice, Ercc1Δ/+ Fvb mice were
bred with Ercc1+/− C57BL/6 mice. Genotype was confirmed using
PCR and Ercc1Δ/− mice were matched with wildtype littermates of the
same sex. After 3–4 months of age, Ercc1Δ/− mice started to develop
tremors and aberrant behavior, and were sacrificed. For induction of
EAE, 10-week-old female C57BL/6 mice (Harlan, The Netherlands)
were immunized with MOG35–55 in complete Freund's adjuvant (CFA)
(Hooke, EK-2110) and injected with pertussis toxin on the day of
immunization and 24 hr later. Mice were monitored daily for develop-
ment of EAE and sacrificed at score 1 (limp tail), score 4 (complete
hind leg paralysis), and remission (partial regain of movement in
hind legs).
2.2 | Acute microglia isolation
Microglia were isolated as described previously (Galatro, Vainchtein,
Brouwer, Boddeke, & Eggen, 2017b). Briefly, mice were perfused
using PBS (Lonza, BE17-512F) and brain and spinal cord were isolated
in HBSS (Gibco, 14170-088) containing 15 mM HEPES (Lonza,
BE17-737E) and 0.6% glucose (Sigma-Aldrich, G8769) (=Medium A).
Tissue was mechanically disrupted to obtain a single cell suspension
and myelin was removed using 24.4% percoll (GE Healthcare,
17-0891-01) density gradient centrifugation at 950g. Cells were
incubated 15 min in anti-Cd16/32 blocking buffer (clone
93, eBioscience, 14-0161-85) and stained with anti-Cd11b-PE-Cy7
(clone M1/70, eBioscience, 25-0112-81), anti-Cd45-FITC (clone
30-F11, eBioscience, 11-0451-85), and anti-Ly6c-APC (clone HK1.4,
Biolegend, 128016) antibodies 30 min on 4C. Cells were sorted on a
MoFlo XDP Cell Sorter (Beckman Coulter) in RNAlater (Qiagen,
76104) in siliconized tubes. Sorted cells were centrifuged at 5,000g
(RNAlater) and lysed in RLT+ lysis buffer (Qiagen, 74034).
2.3 | Immunohistochemistry
Immunohistochemical staining was performed on formalin-fixed
paraffin-embedded (FFPE) or paraformaldehyde (PFA)-fixed frozen
tissue as indicated. Briefly, FFPE tissue was deparaffinized in xylene
(J.T. Baker, 9490) and rehydrated. For human tissue, sodium citrate
(pH 6.0) heat-induced antigen retrieval was performed in a microwave
using a pressure cooker, whereas Tris–EDTA (pH 9.0) was used for
mouse tissue. Endogenous peroxidase activity was blocked in 0.3%
hydrogen peroxide for 30 min and mouse tissue was additionally
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blocked in 10% normal serum. Primary antibodies were applied at 4C
overnight (Supporting Information, Table S1). For human tissue, primary
antibodies were diluted in Normal Antibody Green Bright Diluent
(ImmunoLogic, BD09-500). Fluorophore-conjugated (Molecular Probes)
or biotinylated (Vector) secondary antibodies were applied for 1 hr at
room temperature (RT). For fluorescence staining, tissue was incubated
10 min in Hoechst and human tissue was treated with 0.3% sudan black
to quench autofluorescence. Tyramide Superboost streptavidin kit
(Invitrogen, B40933) was used for VISTA (clone MH5a) according to
manufacturer's instructions. For enzymatic immunostaining, tissue was
incubated 30 min in Vectastain Elite ABC-HRP (Vector, PK-6100) and
immunoreactivity was revealed using 3,30-diaminobenzidine.
2.4 | Primary mouse neonatal microglia culture
Primary neonatal mouse microglia cultures were prepared as
described previously (Schaafsma et al., 2015) with minor deviations.
Briefly, cerebrum from postnatal day 0–2 C57BL/6 mice was minced
and incubated in trypsin-containing medium. After trituration and cen-
trifugation of tissue, cells were plated in flasks and medium (DMEM
(Gibco, 11500416), supplemented with 1 mM sodium pyruvate
(Lonza, BE13-115E), 1× GlutaMAX (Gibco, 35050038), 1% Pen/strep,
and 10% FCS (Gibco, 10500064)) was replaced 24 hr later. Medium
was replaced on Day 4, and on Day 7, medium supplemented with
33% L929 cell-conditioned medium (LCCM) was added. LCCM con-
tains M-CSF to stimulated microglia proliferation. Three days after
LCCM addition, microglia were harvested through shake off and
seeded at 30,000 cells/cm2 in 12-well plates. Twenty-four hours after
seeding, primary neonatal microglia were simulated with 100 ng/ml
Pam3CSK4 (Invivogen, #tlrl-pms), 100 ng/ml LPS (E. coli 0111:B4,
Sigma-Aldrich, L4391), 50 μg/ml PolyI:C (Invivogen, #tlrl-pic), or
10 μg/ml β-glucan (Sigma-Aldrich, G5011).
2.5 | Primary adult rhesus macaque microglia culture
Primary adult rhesus macaque (Macaca mulatta) microglia cultures
were isolated from post mortem brain tissue and cultured as described
previously (Burm et al., 2015). Briefly, male or female rhesus macaque
monkeys (4–9 years old) without neurological symptoms were housed
in outbred breeding colonies. No monkey was sacrificed exclusively
for the generation of the primary cultures. Cubes of 3 g of subcortical
white matter brain tissue were mechanically and enzymatically disso-
ciated and centrifuged. A percoll gradient was used to remove myelin;
other CNS cells and erythrocytes were removed by exposure to hypo-
tonic solution. Isolated microglia were cultured in DMEM (high
glucose)/HAM F10 Nutrient Mixture (supplemented with 10% v/v
heat-inactivated FCS, 0.5 mm glutamax, 50 U/ml penicillin, and
50 μg/ml streptomycin) (Thermo Fisher). After 24 hr, nonadherent
cells and cellular debris were removed and fresh medium containing
20 ng/ml macrophage colony-stimulating factor (M-CSF) (Peprotech)
was added. After 7 days in culture, microglia were treated for 16 hr
with 500 ng/ml Pam3CSK4 (Invivogen), 20 μg/ml Poly I:C (Invivogen),
100 ng/ml LPS (E. coli 026:B6, Sigma-Aldrich, L8274), or 1 μg/ml
CL075 (Invivogen, #tlrl-c75).
2.6 | Gene expression analysis
For quantitative PCR analysis, total RNA was isolated using TRIzol
(Invitrogen, 15596018) (primary microglia) or the RNeasy Micro Plus Kit
(Qiagen, 74034) (acutely isolated microglia) according to the manufac-
turers protocol. Total RNA was reverse-transcribed using the RevertAid
First Strand cDNA Synthesis kit (Thermo Fisher, K1622). Quantitative
PCR was performed using exon–exon spanning primers pairs (Biolegio)
(Supporting Information, Table S2), iTag Universal SYBR Green Super-
mix (Bio-Rad, 172-5125), and a QuantStudio 7 Flex (Thermo Fisher).
2.7 | Flow cytometry
Primary microglia were harvested using Accutase (Sigma-Aldrich,
A6964) and resuspended in medium (HBSS without phenol red
(Gibco, 14175-053), supplemented with 15 mM HEPES, 0.6% glucose,
and 1 mM EDTA (Invitrogen, 15575-020)) after centrifugation. Cells
were incubated 15 min on ice in anti-Cd16/32 Fc blocking solution
and subsequently stained with PE-conjugated anti-VISTA (clone
MIH63, Biolegend, 150204) 30 min on RT. After washing, cells were
analyzed on a MacsQuant (Miltenyi Biotec) flow cytometry analyzer.
Dapi was used to distinguish dead cells.
2.8 | Transcription factor motif enrichment analysis
To determine potential TF binding motifs in ATAC-seq peaks, a motif
enrichment analysis was performed using the motif discovery software
HOMER (version 4.9) (Salk Institute and University of California San
Diego) (Heinz et al., 2010). Peaks on the VISTA locus (eight in total)
were identified in Integrative Genomics Viewer (Broad Institute and
University of California) and sequences were used for HOMER enrich-
ment analysis (findMotifs, homer2). HOMER analysis determines motifs
enriched in sequences compared to scrambled sequences.
2.9 | Statistical analysis
Statistical analyses were performed using GraphPad Prism 7
(GraphPad Software, Inc.). For multiple comparison after LPS and TLR
experiments, a one-way ANOVA including Dunnett's test for multiple
comparison was used. For comparison of gene expression in LPS-
injected mice and Ercc1Δ/−, a (un)paired Student's t test was
performed. All error bars indicate mean  standard deviation (SD).
3 | RESULTS
3.1 | VISTA is primarily expressed by microglia in
human and mouse CNS
Expression of most NCRs (CTLA4, PD-1, PD-L1, and more), but not
VISTA, has been reported in the CNS by microglia, endothelial cells,
astrocytes, oligodendrocytes, and/or neurons (Yshii et al., 2017).
Using a combination of immunohistochemistry and flow cytometry,
we assessed VISTA expression in mouse and human brain.
In both mouse and human brain tissue without apparent CNS
pathology, VISTA immunoreactivity was evident on ramified
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microglia-like cells and on blood vessel structures (Figure 1a,b). Immu-
nofluorescence co-staining of Iba1 and VISTA (mouse) and CD68 and
VISTA (human) revealed a strong co-expression of these proteins
(Figure 1c,d), confirming VISTA expression in microglia.
In accordance with the immunostainings, flow cytometry of whole
mouse brain and spinal cord showed that >95% of Cd11b+ Cd45int
microglia exhibited surface VISTA expression. Furthermore, the vast
majority of Cd11b− Cd45− cells did not express detectable levels of
cell surface VISTA (Figure 1e).
These findings demonstrate that VISTA is primarily expressed by
microglia, and to a lesser extent in blood vessels in the CNS.
3.2 | VISTA expression is abundant in adult microglia
and expression levels are similar to microglia signature
genes
To confirm our observations of VISTA expression in microglia and blood
vessels, we analyzed published RNA-seq data forVISTA expression in dif-
ferent CNS cell types (Zhang et al., 2014, 2016). In mouse brain, VISTA
was abundantly expressed bymicroglia, weakly expressed by endothelial
cells, and was not detected in oligodendrocytes, neurons, and astrocytes
(Figure 2a). In human brain, VISTAwas expressed bymicroglia, but also at
moderate levels by endothelial cells, and at low levels by astrocytes
(Figure 2b). VISTA expression was very low in oligodendrocytes and neu-
rons. Of note, we did not observe any VISTA immunoreactivity in astro-
cytes (Figure 1a,b). Expression by endothelial cells is in line with our
previous findings of VISTA expression in blood vessels.
Next, we investigated a published RNA-seq dataset to determine
VISTA expression in isolated mouse microglia during embryonic and
postnatal development (Matcovitch-Natan et al., 2016). The analysis
revealed that VISTA expression increases during microglia development
(Figure 2c) and was most abundant in adult microglia, independent of
the CNS region (hippocampus, cortex, and spinal cord) (Figure 2c).
To further quantify VISTA expression in adult microglia, we com-
pared VISTA mRNA levels to the expression of microglia signature
genes. In acutely isolated adult microglia from mouse brain, VISTA was
abundantly expressed, similar to levels of Tmem119 and P2ry12, and
other microglia signature genes (Figure 2d). In cultured neonatal
mouse microglia and the BV2 microglial cell line, VISTA expression
was moderate, comparable to expression of Pu.1 (neonatal microglia)
or Cd11b (BV2) (Figure 2d). For quantification of VISTA in human
microglia, we analyzed our published RNA-seq dataset of microglia
FIGURE 1 VISTA is expressed by microglia in mouse and human CNS. (a,b) Representative images of VISTA immunoreactivity in mouse (a) (n = 2)
and human brain (b) (n = 4). Inserts show a 2× magnification of areas (1–3) as indicated. (c,d) Representative images of co-expression of Iba1 (red)
and VISTA (green) in mouse brain (c) (n = 2) and CD68 (red) and VISTA (green) in human brain (d) (n = 4). (e) Representative flow cytometry results
of VISTA cell surface expression in Cd11b+ Cd45int microglia from brain (n = 4) and spinal cord (n = 1) [Color figure can be viewed at
wileyonlinelibrary.com]
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isolated from adult nondiseased human postmortem brain (Galatro
et al., 2017a). VISTA expression was enriched in microglia compared
to unsorted parietal cortex tissue (logFC 4.1), an enrichment compara-
ble to what was observed for microglia signature genes TMEM119,
P2RY12, PU.1, and CD11B (Figure 2e).
In summary, these data demonstrate that VISTA is abundantly
expressed by adult human and mouse microglia, and that expression is
comparable to microglia signature genes.
3.3 | TLR stimulation of primary neonatal mouse and
adult rhesus macaque microglia in vitro leads to
downregulation of VISTA expression
Previous studies have reported an upregulation of several NCRs (PD-1,
PD-L1, and PD-L2) in microglia and other CNS cells during inflammatory
conditions, suggesting a role for NCRs in CNS inflammation. To investigate
the expression changes of VISTA during inflammation, we stimulated neo-
natal mouse microglia and adult rhesus macaque microglia with various
TLR agonists in vitro and determined changes inVISTAmRNA levels.
After stimulation of TLR1/2, 3, 4, and 2/6, VISTA expression was
significantly decreased in neonatal mouse microglia by up to 70%
(Figure 3a). In contrast, Pdl1 expression was increased as described in
literature (Yshii et al., 2017) (Figure 3b). VISTA mRNA decreased as
early as 1–2 hr after LPS stimulation and remained reduced up to
12 hr post-LPS exposure (Figure 3c). Consistently, stimulation of
TLR1/2, 3, 4, and 8 in adult rhesus macaque microglia in vitro also
decreased VISTA expression (Figure 3d).
To show that VISTA surface protein is downregulated as well
upon TLR stimulation, flow cytometry on in vitro LPS-stimulated
primary neonatal mouse microglia was performed. VISTA expression
was significantly reduced 12–48 hr after LPS stimulation (Figure 3e,f ).
Whereas the number of VISTA positive microglia decreased only
mildly (~10% at 24 hr post-LPS) (Figure 3e), the geometric mean fluo-
rescence intensity (gMFI), which reflects surface VISTA levels per cell,
was strongly reduced (~50% at 24 hr post-LPS) (Figure 3f ).
Following all TLR stimulations, Tnfα expression was induced in
microglia, demonstrating their immune activation in this experimental
setup (Supporting Information, Figure S1).
Our experiments show that VISTA expression is decreased in
microglia in response to a range of TLR agonists, which is in contrast
to the increased expression of PD-L1 and other NCRs (Yshii
et al., 2017).
FIGURE 2 VISTA expression is abundant in adult microglia and levels are similar to microglia signature genes. (a,b) VISTA mRNA levels (FPKM) in
different CNS cell types of mouse (a) and human (b), derived from published RNA-seq data (Zhang et al., 2014, 2016). (c) Relative gene expression
levels of VISTA during microglia development in embryonic yolk sac, brain, and during postnatal development until adulthood, derived from
published RNA-seq data (Matcovitch-Natan et al., 2016). (d) Relative mRNA expression levels of VISTA in sorted adult microglia, cultured primary
neonatal microglia, and BV2 cells, measured using RT-qPCR and normalized to Hprt1. (e) LogFC of VISTA enrichment in sorted human microglia
(n = 39) compared to unsorted cortical tissue (n = 16), derived from published RNA-seq data (Galatro et al., 2017a). Error bars indicate
mean  SD. FPKM = fragments per kilobase per million [Color figure can be viewed at wileyonlinelibrary.com]
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3.4 | VISTA expression is reduced upon microglial
activation in vivo
In view of the reduced VISTA expression after TLR stimulation of
microglia in vitro, we next investigated changes in VISTA expression
after microglial activation and inflammation in vivo.
To address changes in microglia VISTA expression during CNS
inflammation, we isolated microglia from mouse CNS at different stages
of EAE (induced by MOG35–55 in CFA), which is a mouse model of
MS. During acute stages of EAE (disease score 1 and 4) microglia obtain
a weak immune-activated phenotype (Vainchtein et al., 2014), indicated
by increased levels of Il1β (Supporting Information, Figure S2a). In remis-
sion, increased Axl and MHC-II component H2Aa expression suggest a
phagocytic and antigen-presenting phenotype of microglia (Supporting
Information, Figure S2a). We observed a significant decrease in VISTA
expression in all stages of EAE (score 1, 4, and remission) in spinal cord,
hindbrain, and forebrain microglia compared to nonimmunized mice
(Figure 4a). In contrast, Pdl1was upregulated in all conditions (Figure 4b).
To further assess VISTA expression changes during microglial
activation, we quantified VISTA mRNA in microglia isolated from
Ercc1Δ/− mice. Ercc1 is a protein essential for nucleotide excision DNA
repair and mutant mice display an accelerated aging phenotype
(Vermeij et al., 2016). Microglia from whole brain of 4-month-old
Ercc1Δ/− mice exhibited increased Il1β and Axl expression (Supporting
Information, Figure S2b), indicating an immune-activated and phago-
cytic phenotype. VISTA expression in these microglia was significantly
reduced compared to wild type (WT) littermates (Figure 4c), whereas
Pdl1 expression was increased (Figure 4d).
These data demonstrate that VISTA expression is decreased in
microglia in different mouse models of CNS inflammation and during
microglial activation, which is in line with our in vitro observations.
3.5 | Reduced VISTA expression in LPS-activated
microglia is accompanied by chromatin remodeling
To determine if changes in VISTA expression are accompanied by
epigenetic alterations, we analyzed a recently generated dataset
containing genome-wide transcriptional changes (RNA-seq), histone
modifications (ChIP-seq), and chromatin accessibility (ATAC-seq) in
isolated microglia after LPS exposure in mice (Zhang et al., in press).
FIGURE 3 TLR stimulation leads to decreased VISTA expression in primary neonatal mouse and adult macaque microglia in vitro. (a,b) Fold change
in VISTA (a) and Pdl1 (b) mRNA in primary neonatal mouse microglia measured using RT-qPCR after 4 hr stimulation with Pam3CSK4 (TLR1/2), PolyI:
C (TLR3), LPS (TLR4), and β-glucan (TLR2/6) compared to untreated control (n = 5). (c) Fold change in VISTA mRNA in primary neonatal mouse
microglia after LPS (TLR4) stimulation over time (0–24 hr) compared to untreated control (n = 3). (d) Fold change in VISTAmRNA in primary adult
rhesus macaque microglia after 16 hr stimulation with Pam3CSK4 (TLR1/2), PolyI:C (TLR3), LPS (TLR4), and CL075 (TLR8) compared to untreated
control (n = 3). (e) Representative flow cytometry histogram showing VISTA cell surface expression in primary neonatal mouse microglia after 0 and
24 hr LPS stimulation. (f ) Geometric mean fluorescence intensity (gMFI) of VISTA in primary neonatal mouse microglia upon (0, 12, 24, and 48 hr)
LPS stimulation (n = 4). Statistical analysis conducted was a one-way ANOVA with Dunnett's test for multiple comparisons. Error bars indicate
mean  SD. *p < .05, **p < .01, ***p < .001, ****p < .0001 [Color figure can be viewed at wileyonlinelibrary.com]
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RNA-seq data indicated that VISTA expression is reduced in
acutely isolated microglia 3 hr after LPS injection (Figure 5a), whereas
Pdl1 expression was upregulated (Figure 5b). These results are in line
with our previous observations of decreased VISTA expression in
microglia during EAE and in Ercc1Δ/− mice. VISTA is located within an
intronic region of CDH23, a gene associated with auditory function
(Johnson et al., 2017). Cdh23 was not altered in response to LPS, dem-
onstrating that changes in VISTA expression were independent of the
Cdh23 gene (Supporting Information, Figure S3a).
To determine if decreased VISTA expression is accompanied by
epigenetic changes in the gene locus, we analysed ChIP-seq and
ATAC-seq datasets. Concomitant with reduced VISTA expression after
LPS exposure, we observed decreased H3K27 histone acetylation
(H3K27ac) upstream of the VISTA gene (Figure 5c). H3K27ac is
enriched on enhancers and associated with active gene transcription.
We next assessed chromatin accessibility using ATAC-seq data.
ATAC-seq provides information about transposase-accessibility of
chromatin at specific locations on the genome (Buenrostro, Wu,
Chang, & Greenleaf, 2015). Transposase-accessible chromatin is also
accessible for transcription factors (TF) and indicated as Peaks (1–8)
on the VISTA gene (Figure 5c). Enrichment analysis for putative TF
binding motifs revealed that 17 consensus sequences were signifi-
cantly enriched in the DNA underlying these peaks (Table 1). Consen-
sus binding sites for Pu.1 (Spi1) and Mafb were among the most
significantly enriched TF motifs, and both proteins are crucial for
microglia function (Matcovitch-Natan et al., 2016; Smith et al., 2013).
In DNA sequences of ATAC peaks that were reduced in microglia
after LPS injection, we detected consensus binding sites for Pu.1,
Rfx6, Elf5, and Sox15 (Peaks 4–6) (Figure 5c and Table 1). In contrast,
Ap4 and Nf1 binding motifs were enriched in DNA sequences of
peaks unaltered by LPS stimulation (Peaks 1–3, 7–8) (Figure 5c and
Table 1).
Our findings show that reduced VISTA expression is accompanied
by altered histone modification enrichments and changes in chromatin
accessibility that are associated with transcriptional repression. Fur-
thermore, the presence of consensus binding sites for Pu.1 and Mafb
on chromatin accessible DNA on the VISTA gene suggests that VISTA
may be regulated by these microglia-specific TF, and that reduced
accessibility of Pu.1, Elf5, and Sox15 to consensus binding sites in
VISTA underlie reduced expression in response to LPS.
3.6 | VISTA expression is differentially regulated in
the human CNS
In view of the observed reduction in VISTA expression during micro-
glial activation in vitro and in vivo, we next assessed VISTA expression
in human brain tissue of young and old individuals, and in septicemia,
MS and AD patients (Supporting Information, Table 3). Based on neu-
ropathological evaluations, one representative patient was selected
for analysis of each condition.
Using IBA1 immunostaining, microglial activation was assessed
based on morphology and staining intensity, and VISTA immunoreac-
tivity was determined in consecutive tissue sections (Figures 6 and 7).
In tissue of a young individual (27 years), microglia exhibited a typical
resting, ramified morphology, and VISTA expression was detected on
microglia and endothelial cells (Figure 6). In both the old individual
FIGURE 4 VISTA expression is reduced in adult microglia in mouse models of CNS pathology. VISTA (a + c) and Pdl1 (b + d) mRNA levels in
acutely isolated adult microglia from spinal cord, hindbrain and forebrain during EAE disease course (C = control, 1 = disease score 1, 4 = disease
score 4, R = remission) (a + b), and from whole brain of accelerated aging Ercc1Δ/− mice and WT littermates (c + d), measured using RT-qPCR and
normalized to Hprt1. Statistical analysis conducted was a one-way ANOVA with Dunnett's test for multiple comparisons (a + b) and a paired
Student's t test for direct comparisons (c + d). Error bars indicate mean  SD.WT = wild type, *p < .05, **p < .01, ***p < .001
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(70 years) and the septicemia patient, we observed only weakly
activated microglia, and VISTA immunoreactivity in microglia was
slightly reduced (Figure 6 and Table 2). VISTA staining of endothelium,
however, did not seem to be affected. In the AD patient, a strong
IBA1 staining intensity suggested microglial activation, which
correlated with strong VISTA expression, and was specifically
observed in microglia clusters (Figure 6). Co-staining of IBA1 and
β-amyloid revealed that these microglia clusters were surrounding
β-amyloid plaque (Supporting Information, Figure S4). No difference in
endothelial VISTA expression was observed. In MS normal-appearing
FIGURE 5 Decreased VISTA expression after LPS injection is associated with chromatin remodeling in microglia. (a,b) RNA-seq counts per million of
VISTA (a) and Pdl1 (b) mRNA expression (n = 3). (c) H3K27ac histone acetylation (top) and ATAC-seq (bottom) peaks corresponding to the VISTA
gene (n = 3). ATAC-seq peaks were numbered 1–8 and peaks that were decreased after LPS stimulation are indicated in red (4–6). Data are derived
from previously generated datasets (Zhang et al., in press). Transcription factor binding motifs enriched in these peaks are listed in Table 1. Error bars
indicate mean  SD. # = differential expression (DE) based on RNA-seq analysis [Color figure can be viewed at wileyonlinelibrary.com]
TABLE 1 Transcription factor motifs enriched in ATAC-seq peaks on the VISTA gene (ordered from high to low enrichment score)
Motif Consensus p value q value (benjamini) # Peaks with motif (of 8)
Pu.1 AGAGGAAGTG 1,00E-05 0.0017 5.0
Rfx6 TGTTKCCTAGCAACM 1,00E-04 0.0079 7.0
Elf5 ACVAGGAAGT 1,00E-03 0.0184 5.0
Sox15 RAACAATGGN 1,00E-03 0.0548 4.0
Mafb WNTGCTGASTCAGCANWTTY 1,00E-03 0.0675 3.0
Zfp281 CCCCTCCCCCAC 1,00E-02 0.1110 2.0
Nr5a2 BTCAAGGTCA 1,00E-02 0.1110 2.0
Znf143 ATTTCCCAGVAKSCY 1,00E-02 0.1110 2.0
Klf10 GGGGGTGTGTCC 1,00E-02 0.1247 3.0
Ap4 NAHCAGCTGD 1,00E-02 0.1657 4.0
Scl AVCAGCTG 1,00E-02 0.2013 8.0
Prdm14 RGGTCTCTAACY 1,00E-02 0.2013 2.0
Fxr, Ir1 AGGTCANTGACCTB 1,00E-02 0.2013 2.0
MafK GCTGASTCAGCA 1,00E-02 0.2013 2.0
Sox4 YCTTTGTTCC 1,00E-02 0.2013 4.0
Elf3 ANCAGGAAGT 1,00E-02 0.2225 3.0
Nf1 YTGCCAAG 1,00E-02 0.2225 6.0
Motifs enriched in peaks decreased upon LPS (Peaks 4–6).
Motifs enriched in peaks unchanged upon LPS (Peaks 1–3, 7, and 8).
Motifs enriched in both unchanged peaks and peaks decreased by LPS.
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white matter (NAWM), microglial activation was low and VISTA was
highly expressed on microglia and endothelium (Figure 7 and Table 2).
Within and around a chronic lesion in the MS tissue, intermediate to
strong IBA1 staining was observed, whereas VISTA staining was
almost absent in microglia and endothelial cells.
To establish a correlation between VISTA expression and CNS
inflammation in these tissues, we performed a co-staining of VISTA
with HLA-DR (Figures 6 and 7). In line with the previous immunostain-
ing, low levels of HLA-DR in the young individual, and positive VISTA
signals in microglia and endothelial cells were observed (Figure 6 and
Table 2). In the old and the septicemia donors, HLA-DR expression was
only slightly increased, but VISTA expression remained unchanged. In
the AD tissue, HLA-DR was highly expressed by microglia, which also
abundantly expressed VISTA. In MS, co-staining revealed a negative
correlation of HLA-DR and VISTA expression (Figure 7 and Table 2).
VISTA was not detected in microglia/macrophages and endothelial cells
at the rim of the lesion; however, a weak VISTA signal was observed in
some amoeboid cells expressing high HLA-DR within the lesion.
Our in situ analyses of human specimens indicate that regulation
of VISTA expression during CNS pathology is more variable in human
disease. In line with our mouse data (Figure 4a), we observed reduced
VISTA expression in MS. Conversely, in AD, VISTA expression posi-
tively correlated with microglial activation.
4 | DISCUSSION
In this article, we demonstrate that VISTA is expressed by mouse and
human microglia and endothelial cells in the CNS, and that expression
is differentially regulated during disease. In view of increasing interest
for the role of NCRs in the CNS, and the unexpected adverse neuro-
logical effects following immunotherapy, we provide first evidence for
a possible function of VISTA in microglia and during CNS pathology.
Key findings include the following: (a) VISTA is abundantly expressed
by human and mouse microglia comparable to microglia signature
genes. (b) VISTA expression is downregulated in mouse and rhesus
FIGURE 6 VISTA expression in young and old individuals, and sepsis and Alzheimer's patients. VISTA and IBA1 immunoreactivity, and
immunofluorescence of HLA-DR (red) and VISTA (green) co-expression in human brain tissue of young, old, sepsis, and AD patients (n = 1) [Color
figure can be viewed at wileyonlinelibrary.com]
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macaque microglia upon TLR ligation in vitro, and in mouse microglia
during EAE, accelerated aging, and by LPS stimulation. (c) Our results
suggest that VISTA expression is potentially regulated by the two
microglia-specific TF, Pu.1, and Mafb, and that reduced VISTA expres-
sion after LPS injection is associated with histone modifications and
reduced chromatin accessibility. (d) Finally, our findings indicate that
VISTA expression is differentially regulated in human CNS pathologies
including MS and AD.
In mouse and human brain, VISTA mRNA and protein were pri-
marily detected in microglia. Surface VISTA was detected on >95% of
microglia in mice, and gene expression in mouse and human microglia
was similar to levels of microglia signature genes. Hence, VISTA is
abundantly expressed by microglia. Regarding VISTA function in T cell
inhibition, it is surprising that expression is high in microglia under
nonpathological conditions, as T cells are not present in healthy brain
parenchyma. However, it is possible that VISTA expression by micro-
glia is necessary to assure T cell suppression during immunosurveil-
lance of the CNS (Korn & Kallies, 2017), or to limit tissue damage in
case of T cell infiltration under pathological conditions. In addition,
other functions of VISTA have been reported, which could play a role
in microglia homeostasis and innate immune response. For example,
Yoon et al. (2015) showed that VISTA expression in phagocytic cells is
essential for uptake of apoptotic cells. Furthermore, VISTA is involved
in the immune response of myeloid cells, as overexpression in human
monocytes leads to spontaneous cytokine secretion (Bharaj et al.,
2014). Thus, VISTA may be involved in immune surveillance and
uptake of apoptotic neurons or other debris by microglia.
Consistent with this argument, our findings indicate that VISTA
expression is regulated similarly to known homeostatic microglia
genes such as TMEM119 and P2RY12. These signature genes are
downregulated upon microglial activation (Grabert et al., 2016).
Expression of P2RY12 is lost in active MS lesions (Zrzavy et al., 2017),
in which microglia obtain an immune-activated phenotype. The
decrease in VISTA expression during microglial activation in mice and
in MS lesions indicates a similar homeostatic function of VISTA. Sup-
porting this notion, we identified consensus binding sites for Pu.1 and
FIGURE 7 VISTA expression is reduced in and around chronic MS lesions. VISTA and IBA1 immunoreactivity, and immunofluorescence of HLA-
DR (red) and VISTA (green) co-expression in different lesion regions (Van Der Valk & De Groot, 2000) of an MS patient (n = 1). NAWM = normal
appearing white matter [Color figure can be viewed at wileyonlinelibrary.com]
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Mafb in accessible chromatin on the VISTA gene, which are TFs pivotal
for microglia homeostatic function. Knockout of Pu.1 in mice leads to a
complete loss of microglia (Smith et al., 2013), and Mafb is involved in
homeostasis of adult microglia (Matcovitch-Natan et al., 2016).
The downregulation of VISTA that we observed in activated
microglia stands in marked contrast to published studies on expres-
sion of other NCRs (Yshii et al., 2017). In microglia, expression of sev-
eral NCRs is induced or upregulated upon inflammatory stimuli (Yshii
et al., 2017), which we confirmed for PD-L1 expression in this study.
Moreover, VISTA expression is upregulated in TLR-stimulated mono-
cytes and macrophages (Bharaj et al., 2014; Wang et al., 2011). This
discrepancy underscores our previous argument that VISTA has addi-
tional functions in microglia that deviate from other NCRs and other
myeloid cells. Considering the function of VISTA in apoptotic cell
clearance and cytokine response (Bharaj et al., 2014; Yoon et al.,
2015), a loss of VISTA in activated microglia may reduce their ability
to clear debris or to mount a cytokine response. However, VISTA may
also function as an NCR in microglia, and downregulation likely has
consequences for CNS pathologies which involve T cell infiltration.
Several studies have shown that knockout of NCRs including VISTA in
mice promotes the development of EAE (Joller et al., 2012; Wang
et al., 2014). Hence, lack of VISTA expression on microglia may pro-
mote T cell infiltration and activation in the CNS, which can exacer-
bate or predispose for diseases such as MS or EAE. The function of
VISTA in microglia with regard to CNS pathology should be evaluated
in further studies.
Our results also indicate a potential underlying epigenetic mecha-
nism by which VISTA expression is reduced upon LPS stimulation in
microglia. We observed decreased H3K27ac enrichment, a histone
modification associated with active transcription. Furthermore, Pu.1,
Rfx6, Elf5, and Sox15 consensus binding motifs in the VISTA gene
exhibited reduced accessibility after LPS stimulation. Together, these
epigenetic alterations likely contribute to reduced expression of
VISTA in LPS-activated microglia.
In line with our findings of decreased VISTA expression in acti-
vated microglia, we observed a strong reduction of VISTA on micro-
glia/macrophages in chronic MS lesion tissue. Strikingly, VISTA
expression was elevated in microglia in NAWM and close to plaques
in the AD patient compared to the young and old individual. There-
fore, expression regulation of VISTA in human CNS disease could
depend on the underlying pathophysiology. In chronic MS lesions,
massive infiltration and unregulated activity of macrophages and lym-
phocytes occur (Van Der Valk & De Groot, 2000). It is possible that
the presence of immune cell infiltrates in MS might facilitate the loss
of VISTA expression, and VISTA deficiency could again augment infil-
tration. In contrast, AD is a neurodegenerative disease which features
endogenous inflammation with absence of parenchymal immune cell
infiltrates (Graeber, Li, & Rodriguez, 2011). In AD, microglia are acti-
vated by amyloid-β (Aβ) and neuronal debris, contributing to clearance,
but also causing tissue damage. A recent study suggests that aggre-
gated Aβ sensed by microglia causes inflammasome activation, which
contributes to progression and spreading of inflammation and Aβ
pathology (Venegas et al., 2017). Furthermore, single-cell RNA-
sequence data suggest that plaque-associated microglia in mice obtain
a Trem2-dependent phagocytic phenotype (Keren-Shaul et al., 2017).
Hence, VISTA expression changes in activated microglia may depend
on environmental cues in CNS pathologies, such as interactions with
peripheral immune infiltrates in MS, or activation by Aβ in AD.
Interestingly, we also observed downregulation of VISTA in endo-
thelial cells in chronic MS lesion. The endothelium is involved in MS
pathology by recruitment of immune cells to the CNS (Yun, Minagar, &
Alexander, 2017). Endothelial cells are involved in antigen presenta-
tion of CNS components to antigen-specific lymphocytes (Galea et al.,
2007; Lopes Pinheiro et al., 2016; Traugott & Raine, 1985). Blocking
co-inhibitory molecules PD-L1 or PD-L2 on human endothelial cells
facilitates transmigration responses of lymphocytes in vitro (Pittet,
Newcombe, Prat, & Arbour, 2011; Rodig et al., 2003). Reduced VISTA
expression on endothelium in MS could therefore promote activation
and transmigration of lymphocytes into the CNS. Additional studies
are needed to assess the effect of VISTA deficiency in endothelial
cells regarding antigen presentation and immune cell infiltration.
In conclusion, we present an elaborate multi-species analysis of
VISTA expression in the CNS, including changes during pathology. We
demonstrate that VISTA is abundantly expressed by microglia, sug-
gesting a functional role in these cells. Differential expression of
VISTA during CNS pathology highlights the importance to further
TABLE 2 Summary of VISTA immunoreactivity in human CNS pathologies
Pathology
Immunohistochemistry Immunofluorescence
Aging, sepsis, AD Microglial activationa VISTA microglia VISTA endothelium HLA-DR VISTA
Young − + + − +
Old ++ +/− + +/− +
Sepsis + +/− + +/− +
AD + ++ + ++ ++
Multiple sclerosis
NAWM − ++ ++ + ++
Chronic lesion rim +/− − + + +
Chronic lesion 1 ++ − +/− ++ −
Chronic lesion 2 ++ +/− − ++ +/−
Note. NAWM = normal appearing white matter.
++, high expression/activation; +, normal expression/activation; +/−, weak expression/activation; −, no expression/activation (expression and activation
scored relative to young individual; i.e., normal VISTA expression and no microglial activation).
a Microglia activation based on IBA1 staining and morphology compared to young individual.
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elucidate the function of VISTA in the CNS. Our study is the first to
show VISTA expression patterns in the CNS, which serves as a basis
for future studies to address the role of VISTA in microglia and during
CNS pathology.
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